Prevalence of Hyperprolactinemia in Patients Undergoing Long-Term Proton Pump Inhibitor Therapy: Hyperprolactinemia in Patients Having Long-Term Proton Pump Inhibitor Therapy

Muhammad Zubair; Javaria Amil; Sadia Noureen; Muhammad Ikram Ul Haq; Saddiqa Azmat; Sadia Majeed

doi:10.54393/pjhs.v5i11.2532

Authors

Muhammad Zubair Department of Medicine, Niazi Medical and Dental College, Sargodha, Pakistan
Javaria Amil Department of Medicine, Niazi Medical and Dental College, Sargodha, Pakistan
Sadia Noureen Department of Medicine, Niazi Medical and Dental College, Sargodha, Pakistan
Muhammad Ikram Ul Haq Department of Medicine, Niazi Medical and Dental College, Sargodha, Pakistan
Saddiqa Azmat Department of Obstetrics and Gynaecology, Niazi Medical and Dental College, Sargodha, Pakistan
Sadia Majeed Department of Pharmacology, Continental Medical College, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i11.2532

Keywords:

Long-Term Therapy, Proton Pump Inhibitors, Hyperprolactinemia, Prolactin

Abstract

Proton pump inhibitors used to treat gastrointestinal disorders cause various threatening effects and lead to an increase in serum prolactin levels. Objectives: To evaluate serum prolactin and macroprolactin levels in long-term proton pump inhibitor therapy patients. Method: An observational cross-sectional study was done between February 2023 and June 2024, at Niazi Welfare Foundation Teaching Hospital, Sargodha after approval from the institutional review board. Patients of either gender using proton pump inhibitors for ≥3 months, alone or in combination with histamine 2 receptor antagonists or pro-kinetics were included to measure serum prolactin levels. A duration of >3 months was taken as long-term therapy to see the impact on prolactin levels. The data were analyzed using SPSS version 25.0. Results: Out of the 166 patients, 102 (61.4%) were female, and 64 (38.6%) were male. The patient's mean age was 42.6 ± 14.3 years, and serum prolactin level was 23.2ng/mL. Among the participants, 97 (58.4%) had normoprolactinemia, while 69 (41.6%) had hyperprolactinemia. A significant increase in hyperprolactinemia with longer proton pump inhibitor treatment duration was revealed. Conclusions: It was concluded that prolonged use of proton pump inhibitors has the potential to raise serum prolactin levels, highlighting the importance of thorough evaluation for optimal clinical management.

References

Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update On De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022 Apr; 162(4): 1334-42. doi: 10.1053/j.gastro.2021.12.247.

Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021 Jan; 13(1). doi: 10.7759/cureus.12759.

Meng X, Zhu X, Li B, Liu J, Zhao J, Wang H et al. Efficacy and Safety of Proton Pump Inhibitors and H2 Receptor Antagonists in the Initial Non-Eradication Treatment of Duodenal Ulcer: A Network Meta-Analysis. Experimental and Therapeutic Medicine. 2023 Jun; 25(6): 1-0. doi: 10.3892/etm.2023.11971.

Deliwala SS, Hamid K, Goyal H, Ponnapalli A, Zayed Y, Bala A et al. Proton Pump Inhibitors Versus Histamine-2-Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Meta-Analysis and Trial Sequential Analysis. Journal of Clinical Gastroenterology. 2022 Mar; 56(3): 204-17. doi: 10.1097/MCG.0000000000001562.

Castellana C, Pecere S, Furnari M, Telese A, Matteo MV, Haidry R et al. Side Effects of Long-Term Use of Proton Pump Inhibitors: Practical Considerations. Polskie Archiwum Medycyny Wewnetrznej. 2021; 131(6): 541-9. doi: 10.20452/pamw.15997.

Thurber KM, Otto AO, Stricker SL. Proton Pump Inhibitors: Understanding the Associated Risks and Benefits of Long-Term Use. American Journal of Health-System Pharmacy. 2023 Apr; 80(8): 487-94. doi: 10.1093/ajhp/zxad009.

O’Leary K. Hyperprolactinemia: Effect on Reproduction, Diagnosis, and Management. Textbook of Assisted Reproduction. 2020: 141-8. doi: 10.1007/978-981-15-2377-9_16.

Ioachimescu AG and Kelestimur F. Drug-induced Hypo-Prolactinemia. Reviews in Endocrine and Metabolic Disorders. 2024 Sep; 25(6): 1-9. doi: 10.1007/s11154-024-09909-6

Ghoreshi ZA, Akbari H, Sharif-Zak M, Arefinia N, Abbasi-Jorjandi M, Asadikaram G. Recent Findings on Hyperprolactinemia and Its Pathological Implications: A Literature Review. Journal of Investigative Medicine. 2022 Oct; 70(7): 1443-51. doi: 10.1136/jim-2022-002351.

Kolnikaj TS, Musat M, Salehidoost R, Korbonits M. Pharmacological Causes of Hyperprolactinemia. Endotext [Internet]. 2024 Jan.

Baldo BA, Pham NH, Baldo BA, Pham NH. Proton Pump Inhibitors. Drug Allergy: Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships. 2021: 521-31. doi: 10.1007/978-3-030-51740-3_12.

Ashfaq M, Khan Q, Haroon MZ, Abid SM, Sharif MJ, Alkahraman YM. Long-Term Proton Pump Inhibitor Therapy and its Effect on Endocrine Hormones in Selected Patient Population. Hormone and Metabolic Research. 2023 Mar; 55(03): 205-11. doi: 10.1055/a-2009-9629.

Prikis M, MacDougall J, Narasimhadevara N. Proton Pump Inhibitor‐Induced Galactorrhea in a Kidney Transplant Recipient: A Friend or Foe? Case Reports in Transplantation. 2020; 2020(1): 8108730. doi: 10.1155/2020/8108730.

He B, Carleton B, Etminan M. Risk of Gynecomastia with Users of Proton Pump Inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019 May; 39(5): 614-8. doi: 10.1002/phar.2245.

Venkatanarasu A, Boddula R, Basavaraju S, Chinte C, Tickoo V. Drug Induced Hyperprolactinemia. Journal of the Endocrine Society. 2021 Apr; 5(Supplement_1): A626-7. doi: 10.1210/jendso/bvab048.1277.

Cano AM, Mendiguchía LJ, Coronado MR, Lozano AG, del Rey-Mejías ÁL, Merino MF, Pinedo MM, Araujo-Castro M. Causes of Hyper-prolactin-aemia in the Primary Care Setting: How to Optimize Hyper-prolactinaemia Management. Endocrinología, Diabetes y Nutrición. 2022 Dec; 69(10): 771-8. doi: 10.1016/j.endinu.2022.01.011.

Kang H. Sample Size Determination and Power Analysis Using the G* Power Software. Journal of Educational Evaluation for Health Professions. 2021 Jul; 18. doi: 10.3352/jeehp.2021.18.17.

Ashfaq M, Khan Q, Haroon MZ, Abid SM, Sharif MJ, Alkahraman YM. Effects of Long-Term Proton Pump Inhibitor Use On Sexual Hormones and Sexual and Reproductive Health in Female Patients. Endocrine. 2024 Feb; 83(2): 494-501. doi: 10.1007/s12020-023-03572-8.

Ashfaq M, Khan AN, Alkahraman YM, Haroon MZ. Long-Term Proton Pump Inhibitors Therapy and Prevalence of Hyper-prolactinaemia: A Cross-Sectional Study in Outpatient Gastroenterology Clinics. The Journal of the Pakistan Medical Association. 2024 Jun; 74(6): 1067-73. doi: 10.47391/JPMA.9541.

Zaharudin MR, Samsudin IN, Abdul Hamid H, Thambiah SC. Reporting of Hyper-prolactinaemia Post-Polyethylene Glycol (PEG) Precipitation at Hospital Tengku Ampuan Rahimah Klang, Malaysia. Malaysian Journal of Medicine and Health Sciences. 2023 Dec; 19. doi: 10.47836/mjmhs.19.s16.2.

Šostarić M, Bokulić A, Marijančević D, Zec I. Optimizing Laboratory Defined Macroprolactin Algorithm. Biochemia Medica. 2019 Jun; 29(2): 346-51. doi: 10.11613/BM.2019.020706.

Che Soh NA, Yaacob NM, Omar J, Mohammed Jelani A, Shafii N, Tuan Ismail TS et al. Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2020 Nov; 17(21): 8199. doi: 10.3390/ijerph17218199.

Lim MH and Ho CK. Macroprolactin Screening in 464 Patients with Hyperprolactinemia. The Malaysian Journal of Pathology. 2022 Aug; 44(2): 261-7.

Hu Y, Ni J, Zhang B, Cheng W, Zhang H, Ye H et al. Establishment of Reference Intervals of Monomeric Prolactin to Identify Macroprolactinemia in Chinese Patients with Increased Total Prolactin. BMC Endocrine Disorders. 2021 Dec; 21: 1-7. doi: 10.1186/s12902-021-00861-z.